Reviews/Alzheimers Disease Treatment/Donanemab slows decline in early Alzheimer's disease
Amyloid Immunotherapy · AD-AMY-02 · v2
Two randomised trials in people with early symptomatic Alzheimer's disease, one large [1] and one smaller earlier one [2], found that donanemab slowed the worsening of thinking and daily function compared with placebo. The larger trial met its main clinical measure and nearly all of its predefined outcomes, and follow-up analyses showed donanemab also lowered the chance of moving to a more advanced disease stage [7]. A three-year extension suggested the benefit grew over time [16]. The size of the benefit, however, is small on the scales used, and whether that is noticeable to patients is debated. Almost all of this evidence comes from a single manufacturer's trial program, so independent confirmation from other investigators is still missing.
A pivotal phase 3 randomised placebo-controlled trial (N=1736) showed donanemab slowed decline on the primary iADRS measure, with a difference of 2.92 points in the combined population and 3.25 points in the low/medium tau population, and on CDR-SB (difference about -0.7), with 23 of 24 gated outcomes significant [1]. A prior phase 2 trial (N=257) showed the same direction on iADRS (difference 3.20; P=0.04) [2]. Progression-risk analyses found donanemab reduced the risk of progression from mild cognitive impairment to mild AD by 33% and from mild to moderate AD by 50% [7]. A three-year long-term extension reported continued CDR-SB benefit against a weighted ADNI external control [16], and treatment-effect and EU-eligible subgroup analyses reinforced the direction [21][4]. The slowing effect was greatest in participants treated earlier [21]. The contested point: The division is over magnitude and independence, not direction: the absolute differences are modest (iADRS ~2.9-3.25 points on a 0-144 scale; CDR-SB ~0.7 [1]) and whether this is clinically meaningful is contested [30][39], while nearly all confirmatory evidence comes from the single Lilly TRAILBLAZER program [1][7][16][21][4]. The three-year benefit rests on a weighted external ADNI control rather than a concurrent randomised placebo [16].
All 39 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alzheimers Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Nearly all confirmatory evidence derives from the single Lilly-sponsored TRAILBLAZER program ([1],[7],[16],[21],[4]) with overlapping sponsorship and authorship; replication is within-program rather than from independent investigators.
Absolute effect sizes are modest (iADRS difference ~2.9-3.25 points on a 0-144 scale [1]; CDR-SB difference ~0.7 [1]); the claim's verb 'slows' is supported, but clinical meaningfulness of this magnitude is contestable — this constrains tier, not direction.
Where it remains uncertain. The absolute effect is small and its clinical meaningfulness is debated [30][39], and almost all confirmatory evidence derives from the single Lilly TRAILBLAZER program, with the three-year benefit measured against an external ADNI control [16].
Aleatory
Cognitive change after treatment varies substantially between patients, and the group-level slowing does not predict any individual's trajectory [39].
Epistemic
Confirmatory evidence is confined to the Lilly TRAILBLAZER program [1][7][16][21][4]; a trial by independent investigators has not yet been run, so this gap is closable with more data.
Inferential
Inferring patient-relevant benefit from iADRS and CDR-SB point differences (~2.9-3.25 and ~0.7 [1]) is a judgement the corpus leaves contested [30][39].
The load-bearing papers from a corpus of 39, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal phase 3 randomised placebo-controlled evidence directly establishing slowed clinical decline.
“Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.”
Panel auditInternal validity: high · scope of inference: Amyloid- and tau-positive early symptomatic AD (MCI/mild dementia), aged mostly ~73, over 76 weeks.Key limitations: 76-week horizon · tau-selected population · high ARIA rate
Independent earlier phase 2 RCT showing the same direction on the primary composite endpoint.
“In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.”
Panel auditInternal validity: medium · scope of inference: Tau- and amyloid-positive early symptomatic AD over 76 weeks.Key limitations: small sample · borderline primary p-value · mixed secondary outcomes
Post-hoc confirmation in the EU-eligible population.
“donanemab significantly slowed disease progression compared to controls with a manageable safety profile in non-carriers and heterozygotes.”
Panel auditInternal validity: medium · scope of inference: APOE e4 non-carriers/heterozygotes without specified exclusions (EU label) over 76-154 weeks.Key limitations: post-hoc subgroup · imputation method · external control for LTE
3 of 39 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Randomised placebo-controlled trials directly and consistently show slowed clinical decline, with sponsor concentration and modest magnitude the only material tempering factors.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent, non-sponsor confirmatory RCT. All confirmatory evidence derives from one manufacturer's program [1][7][16][21][4], so independence of the finding is not established. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial of donanemab in early symptomatic AD led and funded by investigators independent of the sponsor.
Open question: Does donanemab slow clinical decline when tested by investigators independent of the sponsor? Why it is still open: Every confirmatory trial and re-analysis in the corpus is from the Lilly TRAILBLAZER program [1][2][7][16][21][4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19